Learning Objectives

At the end of this educational activity, participants should be able to:

• Recognize the latest systemic therapies for renal cell carcinoma
  
• Combine immune checkpoint inhibitors and targeted agents
  
• Identify and select patients who would benefit from these therapeutic approaches
  
• Monitor treatment response and mitigate adverse events